Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 6/20 | 0.44 |
| ▸ | MMP2 | P08253 | 6/20 | 0.44 |
| ▸ | MMP9 | P14780 | 6/20 | 0.44 |
| ▸ | MMP8 | P22894 | 6/20 | 0.44 |
| ▸ | MMP13 | P45452 | 6/20 | 0.44 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.43 |
| ▸ | BCL2 | P10415 | 8/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.42 |
| ▸ | ITGAV | P06756 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.41 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3092359 | 0.90 | LARS1 (0.44) | MMP1MMP2MMP9MMP8MMP13 | |
| SCHEMBL3091525 | 0.87 | LARS1 (0.48) | LARS1BCL2ALDH1A1MCL1BCL2L1 | |
| SCHEMBL3101091 | 0.86 | ITGB3 (0.51) | MMP1MMP2MMP9MMP8MMP13 | |
| SCHEMBL3100860 | 0.85 | ALDH1A1 (0.43) | MMP1MMP2MMP9MMP8MMP13 | |
| SCHEMBL15000273 | 0.83 | BCL2 (0.48) | MMP1MMP2MMP9MMP8MMP13 | |
| SCHEMBL3097165 | 0.83 | LARS1 (0.45) | LARS1MCL1BCL2L1 | |
| SCHEMBL3097037 | 0.83 | ALDH1A1 (0.46) | ALDH1A1 | |
| SCHEMBL3103784 | 0.83 | MAPT (0.46) | MMP2ALDH1A1 | |
| SCHEMBL3097895 | 0.82 | LARS1 (0.43) | MMP1MMP2MMP9MMP8MMP13 | |
| SCHEMBL3083948 | 0.80 | MAPT (0.44) | MMP1MMP2MMP9MMP8MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2172450-B9 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-10-08 | — | — | EP | disclosed |
| EP-2172450-B1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-10-16 | — | — | EP | disclosed |
| US-8461209-B2 | Malonic acid sulfonamide derivative and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-09 | — | — | US | disclosed |
| EP-2172450-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | REN, AGTR2, AGTR1 | MMP1 1303/4885MMP2 1682/4885MMP9 1227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.